If participant is eligible to continue the study, they will begin taking BMN 673 tablets by mouth every day, starting on the day of their scheduled laparoscopy. Participant will take the study drug for at least 7 days before their scheduled tumor reduction surgery. Participant will stop taking the drug on the day of the surgery and during their recovery time. Once participant has recovered from surgery (about 3-6 weeks later), they will receive standard chemotherapy treatment. The chemotherapy is part of participant's standard of care treatment and is not part of this research study. The type of chemotherapy participant receives will be up to their doctor.